Our Why

“We are leveraging our cutting-edge science to develop lifesaving and life altering therapies for patients with rare immunological diseases.”

Søren Tulstrup, President and CEO

Latest news

Aug 10, 2022

European Society for Organ Transplantation’s (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International

Jul 19, 2022

Regulatory press release
Hansa Biopharma half year report 2022

Jul 18, 2022

Regulatory press release
Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform

Stockholm
...
(...%)

HNSA ... SEK

Annual report 2021	EN	SE
Latest Financial Report	EN	SE

Events & Webcasts

10Aug

Kempen US non-deal road show

New York

11Aug

Canaccord Annual Growth Conference

Boston

18Aug

Penser podden ”Focus on autoimmunity”

Virtual

Introduction to Hansa

Søren Tulstrup, President & CEO

Join Hansa

From our headquarters in Lund, Sweden, we reach around the world. Our dedicated team includes experienced and courageous specialists driven by our purpose to develop lifesaving and life altering therapies for patients living with rare immunological diseases.

Since our founding in 2007, we have worked in cross functional and agile teams. We are gender-balanced, representing a vast number of nationalities and see diversity as an enabler for reaching our corporate objectives. The recruitment of highly motivated, experienced and talented team players supports our development towards a fully integrated global biopharmaceutical company.

In 2020 and 2021, Hansa Biopharma AB was certified as A Great Place to Work company by the independent institute Great Place to Work^® , a global authority on workplace culture, employee experience and leadership behaviour. We are immensely proud.

Careers